A round-up of funding announcements this week. Other companies that have raised new venture capital funding rounds this week include Genespire, HeartVista and Particle Health and Vida.
The company has initiated a Phase II registration trial of a CAR-T that could compete against bluebird and Janssen. CEO Eric Ostertag noted it will dose the first patient in May or June.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
Longitude Capital leads round worth £25 million, which KaNDy will use to advance its non-hormonal menopause drug into Phase IIb clinical trial this year.
Tricida declined to comment about the funding beyond its ?news release, which said that the capital will be used to finance late-stage clinical trials of its lead drug candidate, TRC101.